ALEXANDRIA REAL ESTATE EQUITIES, INC.

Alexandria Real Estate Equities, Inc. (NYSE: ARE) is a mission-driven life science real estate investment trust that pioneered the life science real estate niche upon its founding in 1994. The company operates through its corporate website at www.are.com and serves as the preeminent owner, operator, and developer of collaborative Megacampus ecosystems in premier life science innovation cluster locations across North America.

As of December 31, 2025, Alexandria maintains a substantial asset base comprising approximately 35.9 million rentable square feet of operating properties and 3.5 million rentable square feet of Class A and A+ properties under construction across 340 properties in North America. The company's operating portfolio achieved a 90.9 percent occupancy rate, with a ten-year average occupancy of 95 percent. Investment-grade or publicly traded large-cap tenants represent 53 percent of total annual rental revenue.

Alexandria's geographic footprint spans eight primary markets: Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City, and Texas. The company's tenant base encompasses multinational pharmaceutical companies, public and private biotechnology firms, life science product and service providers, medical device companies, digital health and advanced technology firms, academic and medical research institutions, U.S. government research agencies, nonprofit organizations, and venture capital firms.

The company's business model centers on disciplined capital allocation toward development and redevelopment of high-quality, generic laboratory facilities designed to meet diverse tenant requirements. Alexandria also maintains a venture capital platform providing strategic capital to transformative life science companies. The company employs 514 people as of December 31, 2025, with executive and senior management teams averaging 24 years of real estate experience, including 13 years with Alexandria.

Alexandria's competitive advantages derive from its pioneering market position, deep relationships within the life science industry, expertise in creating dynamic collaborative ecosystems, and proven track record of generating higher occupancy levels, longer lease terms, and superior returns. The company maintains a balanced financial strategy emphasizing liquidity, diverse capital sources, and leverage-neutral growth supported by expanding EBITDA.